Segregation of NF-κB activation through NEMO/IKKγ by Tax and TNFα: Implications for stimulus-specific interruption of oncogenic signaling

Hidekatsu Iha, Karen Kibler, Venkat R.K. Yedavalli, Jean Marie Peloponese, Kerstin Haller, Akiko Miyazato, Takefumi Kasai, Kuan Teh Jeang

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Nuclear factor-κB essential modulator (NEMO), also called IKKγ, has been proposed as a 'universal' adaptor of the I-κB kinase (IKK) complex for stimuli such as proinflammatory cytokines, microbes, and the HTLV-I Tax oncoprotein. Currently, it remains unclear whether the many signals that activate NF-κB through NEMO converge identically or differently. We have adopted two approaches to answer this question. First, we generated and targeted intracellularly three NEMO-specific monoclonal antibodies (mAbs). These mAbs produced two distinct intracellular NF-κB inhibition profiles segregating TNFα from Tax activation. Second, using NEMO knockout mouse fibroblasts and 10 NEMO mutants, we found that different regions function in trans either to complement or to inhibit dominantly TNFα, IL-1β, or Tax activation of NF-κB. For instance, NEMO (1-245 amino acids) supported Tax-mediated NF-κB activation, but did not serve TNFα- or IL-1β signaling. Altogether, our findings indicate that while NEMO 'universally' adapts numerous NF-κB activators, it may do so through separable domains. We provide the first evidence that selective targeting of NEMO can abrogate oncogenic Tax signaling without affecting signals used for normal cellular metabolism.

Original languageEnglish (US)
Pages (from-to)8912-8923
Number of pages12
JournalOncogene
Volume22
Issue number55
DOIs
StatePublished - Dec 4 2003
Externally publishedYes

Fingerprint

Interleukin-1
Monoclonal Antibodies
Human T-lymphotropic virus 1
Oncogene Proteins
Knockout Mice
Phosphotransferases
Fibroblasts
Cytokines
Amino Acids

Keywords

  • Adult T-cell leukemia
  • HTLV-I
  • NEMO/IKKγ
  • NF-κB
  • Oncogenic transformation
  • Tax
  • TNFα

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Segregation of NF-κB activation through NEMO/IKKγ by Tax and TNFα : Implications for stimulus-specific interruption of oncogenic signaling. / Iha, Hidekatsu; Kibler, Karen; Yedavalli, Venkat R.K.; Peloponese, Jean Marie; Haller, Kerstin; Miyazato, Akiko; Kasai, Takefumi; Jeang, Kuan Teh.

In: Oncogene, Vol. 22, No. 55, 04.12.2003, p. 8912-8923.

Research output: Contribution to journalArticle

Iha, Hidekatsu ; Kibler, Karen ; Yedavalli, Venkat R.K. ; Peloponese, Jean Marie ; Haller, Kerstin ; Miyazato, Akiko ; Kasai, Takefumi ; Jeang, Kuan Teh. / Segregation of NF-κB activation through NEMO/IKKγ by Tax and TNFα : Implications for stimulus-specific interruption of oncogenic signaling. In: Oncogene. 2003 ; Vol. 22, No. 55. pp. 8912-8923.
@article{e0e0a36c014a4a75a92b1729cdadf96a,
title = "Segregation of NF-κB activation through NEMO/IKKγ by Tax and TNFα: Implications for stimulus-specific interruption of oncogenic signaling",
abstract = "Nuclear factor-κB essential modulator (NEMO), also called IKKγ, has been proposed as a 'universal' adaptor of the I-κB kinase (IKK) complex for stimuli such as proinflammatory cytokines, microbes, and the HTLV-I Tax oncoprotein. Currently, it remains unclear whether the many signals that activate NF-κB through NEMO converge identically or differently. We have adopted two approaches to answer this question. First, we generated and targeted intracellularly three NEMO-specific monoclonal antibodies (mAbs). These mAbs produced two distinct intracellular NF-κB inhibition profiles segregating TNFα from Tax activation. Second, using NEMO knockout mouse fibroblasts and 10 NEMO mutants, we found that different regions function in trans either to complement or to inhibit dominantly TNFα, IL-1β, or Tax activation of NF-κB. For instance, NEMO (1-245 amino acids) supported Tax-mediated NF-κB activation, but did not serve TNFα- or IL-1β signaling. Altogether, our findings indicate that while NEMO 'universally' adapts numerous NF-κB activators, it may do so through separable domains. We provide the first evidence that selective targeting of NEMO can abrogate oncogenic Tax signaling without affecting signals used for normal cellular metabolism.",
keywords = "Adult T-cell leukemia, HTLV-I, NEMO/IKKγ, NF-κB, Oncogenic transformation, Tax, TNFα",
author = "Hidekatsu Iha and Karen Kibler and Yedavalli, {Venkat R.K.} and Peloponese, {Jean Marie} and Kerstin Haller and Akiko Miyazato and Takefumi Kasai and Jeang, {Kuan Teh}",
year = "2003",
month = "12",
day = "4",
doi = "10.1038/sj.onc.1207058",
language = "English (US)",
volume = "22",
pages = "8912--8923",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "55",

}

TY - JOUR

T1 - Segregation of NF-κB activation through NEMO/IKKγ by Tax and TNFα

T2 - Implications for stimulus-specific interruption of oncogenic signaling

AU - Iha, Hidekatsu

AU - Kibler, Karen

AU - Yedavalli, Venkat R.K.

AU - Peloponese, Jean Marie

AU - Haller, Kerstin

AU - Miyazato, Akiko

AU - Kasai, Takefumi

AU - Jeang, Kuan Teh

PY - 2003/12/4

Y1 - 2003/12/4

N2 - Nuclear factor-κB essential modulator (NEMO), also called IKKγ, has been proposed as a 'universal' adaptor of the I-κB kinase (IKK) complex for stimuli such as proinflammatory cytokines, microbes, and the HTLV-I Tax oncoprotein. Currently, it remains unclear whether the many signals that activate NF-κB through NEMO converge identically or differently. We have adopted two approaches to answer this question. First, we generated and targeted intracellularly three NEMO-specific monoclonal antibodies (mAbs). These mAbs produced two distinct intracellular NF-κB inhibition profiles segregating TNFα from Tax activation. Second, using NEMO knockout mouse fibroblasts and 10 NEMO mutants, we found that different regions function in trans either to complement or to inhibit dominantly TNFα, IL-1β, or Tax activation of NF-κB. For instance, NEMO (1-245 amino acids) supported Tax-mediated NF-κB activation, but did not serve TNFα- or IL-1β signaling. Altogether, our findings indicate that while NEMO 'universally' adapts numerous NF-κB activators, it may do so through separable domains. We provide the first evidence that selective targeting of NEMO can abrogate oncogenic Tax signaling without affecting signals used for normal cellular metabolism.

AB - Nuclear factor-κB essential modulator (NEMO), also called IKKγ, has been proposed as a 'universal' adaptor of the I-κB kinase (IKK) complex for stimuli such as proinflammatory cytokines, microbes, and the HTLV-I Tax oncoprotein. Currently, it remains unclear whether the many signals that activate NF-κB through NEMO converge identically or differently. We have adopted two approaches to answer this question. First, we generated and targeted intracellularly three NEMO-specific monoclonal antibodies (mAbs). These mAbs produced two distinct intracellular NF-κB inhibition profiles segregating TNFα from Tax activation. Second, using NEMO knockout mouse fibroblasts and 10 NEMO mutants, we found that different regions function in trans either to complement or to inhibit dominantly TNFα, IL-1β, or Tax activation of NF-κB. For instance, NEMO (1-245 amino acids) supported Tax-mediated NF-κB activation, but did not serve TNFα- or IL-1β signaling. Altogether, our findings indicate that while NEMO 'universally' adapts numerous NF-κB activators, it may do so through separable domains. We provide the first evidence that selective targeting of NEMO can abrogate oncogenic Tax signaling without affecting signals used for normal cellular metabolism.

KW - Adult T-cell leukemia

KW - HTLV-I

KW - NEMO/IKKγ

KW - NF-κB

KW - Oncogenic transformation

KW - Tax

KW - TNFα

UR - http://www.scopus.com/inward/record.url?scp=0347363826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347363826&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1207058

DO - 10.1038/sj.onc.1207058

M3 - Article

C2 - 14654787

AN - SCOPUS:0347363826

VL - 22

SP - 8912

EP - 8923

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 55

ER -